---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000083"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:04:38.921433+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance

## Summary
- Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).
- GAAP net loss $(2.7)M ($(0.14)/share); adjusted non-GAAP diluted EPS $1.02; adjusted EBITDA $33.2M.
- Raised FY 2024 guidance: rev $540M-$560M, adj. EBITDA $140M-$150M, adj. EPS $4.38-$4.82.
- On track to acquire Alimera Sciences (~$5.50/sh cash + CVR) in Q3 2024, adding ILUVIEN and YUTIQ.

## SEC filing metadata
- accession: 0001023024-24-000083
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/0001023024-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/ani-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000083
- JSON: https://secwatch.observer/filing/0001023024-24-000083.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.